OTU deubiquitinase 4Genealiases: DUBA6 · HIN1 · HSHIN1
Q-omics provides the consensus-scored OTUD4 profile across patient tissues and cancer cell-line models. OTUD4 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in LGG. Among the 18 cancer types available for tumor–normal comparison, OTUD4 is differentially expressed in 11, with the highest sampling consensus in HNSC. Additionally, OTUD4 RNA expression shows 21,297 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight LGG, HNSC, and ACC as cancer lineages where OTUD4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for OTUD4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes OTUD4 survival associations across molecular data types. OTUD4 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (8) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible OTUD4 RNA expression–survival associations across cancer types. High OTUD4 expression shows unfavorable associations in LGG and PAAD, but favorable associations in BRCA, KIRC, UCS and READ. The LGG Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LGG as the clearest survival context for OTUD4 RNA expression.
This table summarizes OTUD4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 4. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for OTUD4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. OTUD4 shows lower tumor expression in THCA and UCEC and higher tumor expression in HNSC, STAD, CHOL and ESCA. The HNSC box plot shows higher OTUD4 RNA expression in tumor versus normal tissue (log2 FC = +0.549, t-test p < 0.001).
This table shows molecular features associated with OTUD4 in patient tissues and cancer cell lines. In patient samples, OTUD4 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, OTUD4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LARGE_INTESTINE.
